|
1
|
Wang Y, Liu P, Qiu L, Sun Y, Zhu M, Gu L,
Di W and Duan Y: Toxicity and therapy of cisplatin-loaded EGF
modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice.
Biomaterials. 34:4068–4077. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu YJ, Neuwelt AJ, Muldoon LL and Neuwelt
EA: Acetaminophen enhances cisplatin- and paclitaxel-mediated
cytotoxicity to SKOV3 human ovarian carcinoma. Anticancer Res.
33:2391–2400. 2013.PubMed/NCBI
|
|
3
|
Ong PS, Chan SY and Ho PC: Microarray
analysis revealed dysregulation of multiple genes associated with
chemoresistance to As2O3 and increased tumor
aggressiveness in a newly established arsenic-resistant ovarian
cancer cell line, OVCAR-3/AsR. Eur J Pharm Sci. 45:367–378. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tang D, Kang R, Zeh HJ III and Lotze MT:
High-mobility group box 1 and cancer. Biochim Biophys Acta.
1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu D, Ding Y, Wang S, Zhang Q and Liu L:
Increased expression of high mobility group box 1 (HMGB1) is
associated with progression and poor prognosis in human
nasopharyngeal carcinoma. J Pathol. 216:167–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Beeghly A, Katsaros D, Chen H, Fracchioli
S, Zhang Y, Massobrio M, Risch H, Jones B and Yu H: Glutathione
S-transferase polymorphisms and ovarian cancer treatment and
survival. Gynecol Oncol. 100:330–337. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stengel C, Newman SP, Leese MP, Potter BV,
Reed MJ and Purohit A: Class III beta-tubulin expression and in
vitro resistance to microtubule targeting agents. Br J Cancer.
102:316–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Quinn JE, James CR, Stewart GE, Mulligan
JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH and Harkin
DP: BRCA1 mRNA expression levels predict for overall survival in
ovarian cancer after chemotherapy. Clin Cancer Res. 13:7413–7420.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moscat J, Diaz-Meco MT and Wooten MW:
Signal integration and diversification through the p62 scaffold
protein. Trends Biochem Sci. 32:95–100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kobayashi H, Tanisaka K, Doi O, Kodama K,
Higashiyama M, Nakagawa H, Miyake M, Taki T, Hara S, et al: An in
vitro chemosensitivity test for solid human tumors using collagen
gel droplet embedded cultures. Int J Oncol. 11:449–455.
1997.PubMed/NCBI
|
|
11
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sakamoto M, Kondo A, Kawasaki K, Goto T,
Sakamoto H, Miyake K, Koyamatsu Y, Akiya T, Iwabuchi H, Muroya T,
et al: Analysis of gene expression profiles associated with
cisplatin resistance in human ovarian cancer cell lines and tissues
using cDNA microarray. Hum Cell. 14:305–315. 2001.PubMed/NCBI
|
|
13
|
Takano M, Kudo K, Goto T, Yamamoto K, Kita
T and Kikuchi Y: Analyses by comparative genomic hybridization of
genes relating with cisplatin-resistance in ovarian cancer. Hum
Cell. 14:267–271. 2001.PubMed/NCBI
|
|
14
|
Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu
Y, Xie M, Yin X, Livesey KM, Lotze MT, et al: HMGB1-induced
autophagy promotes chemotherapy resistance in leukemia cells.
Leukemia. 25:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miki Y, Swensen J, Shattuck-Eidens D,
Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM,
Ding W, et al: A strong candidate for the breast and ovarian cancer
susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garvin AM, Attenhofer-Haner M and Scott
RJ: BRCA1 and BRCA2 mutation analysis in 86 early onset
breast/ovarian cancer patients. J Med Genet. 34:990–995. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Greggio E, Lewis PA, van der Brug MP,
Ahmad R, Kaganovich A, Ding J, Beilina A, Baker AK and Cookson MR:
Mutations in LRRK2/dardarin associated with Parkinson disease are
more toxic than equivalent mutations in the homologous kinase
LRRK1. J Neurochem. 102:93–102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Haugarvoll K, Toft M, Ross OA, White LR,
Aasly JO and Farrer MJ: Variants in the LRRK1 gene and
susceptibility to Parkinson's disease in Norway. Neurosci Lett.
416:299–301. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu
L, Wang T and Liu B: ERCC1 and BRCA1 mRNA expression levels in
metastatic malignant effusions is associated with chemosensitivity
to cisplatin and/or docetaxel. BMC Cancer. 8:972008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu H, Su J, Xu Y, Kang J, Li H, Zhang L,
Yi H, Xiang X, Liu F and Sun L: p62/SQSTM1 involved in cisplatin
resistance in human ovarian cancer cells by clearing ubiquitinated
proteins. J Eur Cancer. 47:1585–1594. 2011. View Article : Google Scholar
|
